EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting Force-Regulated FimH Adhesin: Assays, Mannosides, and Biologics for Anti-Virulence Therapy of UPEC Infection

Mohor Mitra, Zhilei Chen iD

ACS Infectious Diseases · 17.10.2026

DOI: 10.1021/acsinfecdis.6c00689 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ACS Infectious Diseases, online erschienen am 17.10.2026. Verfasst von Mohor Mitra und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbial Pathogenesis and Immunology, Texas A&M University, Bryan, Texas77807, United States. Hauptthemen laut MEDLINE: Fimbriae Proteins, Adhesins, Escherichia coli, Mannosides, Uropathogenic Escherichia coli. Die Arbeit nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, Texas A and M University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Urinary tract infections (UTIs) are among the most common bacterial infections, and recurrent UTIs caused by uropathogenic Escherichia coli (UPEC) drive antibiotic use and antimicrobial resistance. FimH, the mannose-binding adhesin at the tip of type 1 pili, is a central UPEC virulence factor. Under shear force, FimH switches from a low-affinity, tense state to a high-affinity, relaxed state, strengthening adhesion during urine flow. This catch-bond behavior makes FimH a promising anti-virulence target, though a difficult one to drug. Here, we review strategies to target FimH, including monovalent and multivalent mannosides, vaccines, conformation-selective monoclonal antibodies, and de novo engineered miniproteins, together with the assays used to quantify FimH-ligand binding and UPEC adhesion. Clinical translation has been limited by assay-dependent potency, urinary pharmacokinetics, and intracellular reservoirs. We posit that effective FimH-targeted therapy requires alignment among inhibitor mechanism, FimH conformational state, bladder lumen exposure, and infection stage, which in turn defines realistic roles in prevention, early intervention, and combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fimbriae ProteinsAdhesins, Escherichia coliMannosidesUropathogenic Escherichia coliEscherichia coli InfectionsUrinary Tract InfectionsBiological ProductsAnti-Bacterial AgentsHumansAnimalsVirulenceBacterial AdhesionVirulence Factors

Stichwörter der Autor:innen

FimHUPECantivirulencemannosides

Substanzen

Fimbriae ProteinsAdhesins, Escherichia colifimH protein, E coliMannosidesBiological ProductsAnti-Bacterial AgentsVirulence Factors

Autor:innen und Institutionen

  • Department of Microbial Pathogenesis and Immunology, Texas A&M University, Bryan, Texas77807, United States.
  • Genetics and Genomics Interdisciplinary Program, Texas A&M University, College Station, Texas77843, United States.
  • Department of Biochemistry and Biophysics, Texas A&M University, College Station, Texas77843, United States.

ORCID-Profile: Zhilei Chen

Förderung

  • National Institute of Allergy and Infectious Diseases
  • Texas A and M University

Zitieren

APA

Mitra, M., & Chen, Z. (2026). Targeting Force-Regulated FimH Adhesin: Assays, Mannosides, and Biologics for Anti-Virulence Therapy of UPEC Infection. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.6c00689

Vancouver

Mitra M, Chen Z. Targeting Force-Regulated FimH Adhesin: Assays, Mannosides, and Biologics for Anti-Virulence Therapy of UPEC Infection. ACS Infectious Diseases. 2026. doi:10.1021/acsinfecdis.6c00689

BibTeX
@article{Mitra2026,
  author = {Mitra, Mohor and Chen, Zhilei},
  title = {Targeting Force-Regulated FimH Adhesin: Assays, Mannosides, and Biologics for Anti-Virulence Therapy of UPEC Infection},
  journal = {ACS Infectious Diseases},
  year = {2026},
  doi = {10.1021/acsinfecdis.6c00689}
}
Kostenlos starten →